Loading...
In 2008, a meta-analytic review of controlled trials by the U.S. FDA found a nearly doubled risk for incidentally reported suicidal ideation and attempts with anticonvulsants versus placebo, prompting product-label warnings. However, the analysis left uncertainties about risks with dissimilar anticonvulsants and in clinical subgroups, actual mortality rates, and the validity of research methods (CNS Drugs 2009; 23:281; Pharmacoepidemiol Drug Saf 2010; 19:525; and Baldessarini RJ and Tondo L. Psychopharmacology for suicide prevention. In: Pompili M and Tatarelli R, eds. Evidence-Based Practice in Suicidology: A Sourcebook. Hogrefe Publishing; 2010). This study was a case-control analysis of data on 9415 epilepsy patients from a prospective g…